{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:31:38Z","timestamp":1790753498837,"version":"4.1.0"},"reference-count":59,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Medicinal Research Reviews"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the role of baricitinib alone or in combination with other therapies as a treatment for patients with COVID\u201019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Systematic literature search was conducted in the WHO COVID\u201019 coronavirus disease database to find clinical studies on use of baricitinib for treatment of COVID\u201019 between December 1, 2019 and September 30, 2021. Two independent set of reviewers identified the eligible studies fulfilling the inclusion criteria, relevant data was extracted and a qualitative synthesis of evidence performed. The risk of bias was evaluated with validated tools.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 267 articles were found to be eligible after primary screening of titles and abstracts. Following assessment of full texts, 19 studies were finally included for this systematic review, out of which 16 are observational, and 3 are interventional studies. Collating the results from these observational and interventional studies, baricitinib used as add\u2010on to standard therapy, either alone or in combination with other drugs, was found to have favorable outcomes in hospitalized patients with moderate to severe COVID\u201019. Furthermore, ongoing trials indicate that the drug is being extensively studied across the world for its safety and efficacy in COVID\u201019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Baricitinib significantly improves clinical outcomes in hospitalized patients with COVID\u201019 pneumonia, and further evidence will establish the drug as a standard treatment among such patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/med.21951","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T06:28:20Z","timestamp":1679552900000},"page":"1322-1345","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Use of baricitinib in treatment of COVID\u201019: a systematic review"],"prefix":"10.1002","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6730-5886","authenticated-orcid":false,"given":"Ananyan","family":"Sampath","sequence":"first","affiliation":[{"name":"Department of Pharmacology All India Institute of Medical Sciences  Bhopal Madhya Pradesh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7502-8222","authenticated-orcid":false,"given":"Aditya","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Department of Pharmacology All India Institute of Medical Sciences  Bhopal Madhya Pradesh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5424-4754","authenticated-orcid":false,"given":"Shubham","family":"Atal","sequence":"additional","affiliation":[{"name":"Department of Pharmacology All India Institute of Medical Sciences  Bhopal Madhya Pradesh India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3211-1122","authenticated-orcid":false,"given":"Ratinder","family":"Jhaj","sequence":"additional","affiliation":[{"name":"Department of Pharmacology All India Institute of Medical Sciences  Bhopal Madhya Pradesh India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Coronavirus [Internet]. 2021.https:\/\/www.who.int\/westernpacific\/health-topics\/coronavirus"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"e_1_2_10_4_1","unstructured":"WHO. Coronavirus (COVID\u201019) dashboard [Internet]. 2021.https:\/\/covid19.who.int"},{"key":"e_1_2_10_5_1","unstructured":"COVID\u201019 Treatment Guidelines.\u00a0Guidelines introduction [Internet]. 2021.https:\/\/www.covid19treatmentguidelines.nih.gov\/introduction\/"},{"key":"e_1_2_10_6_1","unstructured":"FDA. Coronavirus (COVID\u201019) update: FDA authorizes drug combination for treatment of COVID\u201019 [Internet]. 2020.\u00a0https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19"},{"key":"e_1_2_10_7_1","unstructured":"Fact sheet for patients parents and caregivers emergency use authorization (EUA) of baricitinib [Internet]. Eli Lilly and Company.\u00a02020.https:\/\/www.fda.gov\/media\/143824\/download"},{"key":"e_1_2_10_8_1","unstructured":"PINHOAC.EMA starts evaluating use of Olumiant in hospitalised COVID\u201019 patients requiring supplemental oxygen [Internet]. European Medicines Agency.2021.https:\/\/www.ema.europa.eu\/en\/news\/ema-starts-evaluating-use-olumiant-hospitalised-covid-19-patients-requiring-supplemental-oxygen"},{"key":"e_1_2_10_9_1","unstructured":"Lilly accelerating baricitinib's availability in India following receipt of permission for restricted emergency use as a COVID\u201019 therapy via donations and licensing agreements.\u00a0Eli Lilly and Company [Internet].2021.https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lilly-accelerating-baricitinibs-availability-india-following"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0723-3"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389450117666161207163054"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.10.022"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30628-0"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.04.017"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.06.052"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000508247"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abc5367"},{"key":"e_1_2_10_18_1","unstructured":"WHO\u2010COVID\u201019: global literature on coronavirus disease [Internet].\u00a02021.https:\/\/search.bvsalud.org\/global-literature-on-novel-coronavirus-2019-ncov\/?u_filter%5B%5D=fulltext%26u_filter%5B%5D=db%26u_filter%5B%5D=collection%26u_filter%5B%5D=mj_cluster%26u_filter%5B%5D=type_of_study%26u_filter%5B%5D=clinical_aspect%26u_filter%5B%5D=la%26u_filter%5B%5D=year_cluster%26u_filter%5B%5D=ta_cluster%26fb=ta_cluster%3A70%26output=site%26lang=en%26from=1%26sort=DATENTRY_DESC%26format=summary%26count=20%26page=1%26skfp=%26index=tw%26q=Baricitinib%26where=%26range_year_start=%26range_year_end=%26range_year_start=%26range_year_end=#ta_cluster"},{"key":"e_1_2_10_19_1","unstructured":"COVID\u201019 Treatment Guidelines.\u00a0Clinical spectrum [Internet]. 2021.https:\/\/www.covid19treatmentguidelines.nih.gov\/overview\/clinical-spectrum\/"},{"key":"e_1_2_10_20_1","unstructured":"CochraneT.\u00a0Assessing risk of bias in a randomized trial [Internet].\u00a02021.\u00a0"},{"key":"e_1_2_10_21_1","unstructured":"NHLBI NIH [Internet]. Study quality assessment tools.2021.https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06119-2"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1515\/med-2021-0010"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa879"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI141772"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa563"},{"key":"e_1_2_10_27_1","unstructured":"RosasJ Lia\u00f1oFP Cant\u00f3ML et al. Experience with the use of baricitinib and tocilizumab monotherapy or combined in patients with interstitial pneumonia secondary to coronavirus COVID19: a real\u2010world study reumatol Cl\u00ednica [Internet].\u00a02020.https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1699258X20302710"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3594565"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001439"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2021.05.009"},{"key":"e_1_2_10_31_1","article-title":"The effect of baricitinib usage on the clinical and biochemical profiles of Covid\u201019 patients\u2014a retrospective observational study","author":"Amarnath A","year":"2021","journal-title":"Cold Spring Harb Lab"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10174019"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa587"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2021-002741"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.17357"},{"key":"e_1_2_10_36_1","doi-asserted-by":"crossref","unstructured":"MarconiVC RamananAV BonoS et al.\u00a0Efficacy and safety of baricitinib in patients with COVID\u201019 infection: results from the randomised double\u2010blind placebo\u2010controlled parallel\u2010group COV\u2010BARRIER phase 3 trial medRxiv.\u00a02021.","DOI":"10.1101\/2021.04.30.21255934"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-03406-3"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031994"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2021.07.004"},{"key":"e_1_2_10_40_1","unstructured":"Risk of bias tools\u2010RoB 2 tool [Internet]. 2021.\u00a0https:\/\/www.riskofbias.info\/welcome\/rob-2-0-tool"},{"key":"e_1_2_10_41_1","unstructured":"HallF.mulTi\u2010Arm therapeutic study in pre\u2010ICu patients admitted with Covid\u201019\u2014repurposed drugs (TACTIC\u2010R) [Internet].2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04390464"},{"key":"e_1_2_10_42_1","unstructured":"National Institute of Allergy and Infectious Diseases (NIAID). A Multicenter adaptive randomized blinded controlled trial of the safety and efficacy of investigational therapeutics for the treatment of COVID\u201019 in hospitalized adults (ACTT\u20104) [Internet].2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04640168"},{"key":"e_1_2_10_43_1","unstructured":"TombettiE.Factorial multicentric randomized clinical trial of remdesivir and immunotherapy in combination with dexamethasone for moderate COVID\u201019 (the AMMURAVID trial) [Internet].\u00a02021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04832880"},{"key":"e_1_2_10_44_1","unstructured":"Cumulative adaptive multiarm multistage and multicentre randomized clinical trial with immunotherapy for Moderate COVID\u201019 [Internet]. 2021.https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-001854-23\/IT"},{"key":"e_1_2_10_45_1","unstructured":"CantiniF.Baricitinib combined with antiviral therapy in symptomatic patients infected by COVID\u201019: an open\u2010label pilot study [Internet].2021.\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04320277"},{"key":"e_1_2_10_46_1","unstructured":"University of Colorado Denver. Safety and efficacy of baricitinib for COVID\u201019 [Internet]. 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04340232"},{"key":"e_1_2_10_47_1","unstructured":"Baricitinib for coRona Virus pnEumonia (COVID\u201019): a THerapeutic trial\u2014full text view\u2014ClinicalTrials.gov [Internet]. 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04399798"},{"key":"e_1_2_10_48_1","unstructured":"MenichettiF.BARICIVID\u201019 STUDY: multicentre randomised phase IIa clinical trial evaluating efficacy and tolerability of baricitinib as add\u2010on treatment of in\u2010patients with COVID\u201019 compared to standard therapy [Internet].2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04393051"},{"key":"e_1_2_10_49_1","unstructured":"University of Southern California. A phase II randomized double\u2010blind trial of baricitinib or placebo combined with antiviral therapy in patients with moderate and severe COVID\u201019 [Internet].2021.\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04373044"},{"key":"e_1_2_10_50_1","unstructured":"Hospital Universitario de Fuenlabrada. Prospective phase II randomized open\u2010label parallel group study to evaluate the efficacy of baricitinib imatinib or supportive treatment in patients with SARS Cov2 pneumonia [Internet].2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04346147"},{"key":"e_1_2_10_51_1","unstructured":"BarrettL.Treatment of moderate to severe coronavirus disease (COVID\u201019) in hospitalized patients [Internet].2020.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04321993"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05072-4"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-04535-4"},{"key":"e_1_2_10_54_1","unstructured":"NIH closes enrollment in trial comparing COVID\u201019 treatment regimens [Internet]. National Institutes of Health (NIH). 2021.https:\/\/www.nih.gov\/news-events\/news-releases\/nih-closes-enrollment-trial-comparing-covid-19-treatment-regimens"},{"key":"e_1_2_10_55_1","unstructured":"Overview | Baricitinib for treating moderate to severe atopic dermatitis | Guidance | NICE [Internet]. NICE.\u00a02021.https:\/\/www.nice.org.uk\/guidance\/ta681"},{"key":"e_1_2_10_56_1","unstructured":"Update on Omicron [Internet]. 2021.https:\/\/www.who.int\/news\/item\/28-11-2021-update-on-omicron"},{"key":"e_1_2_10_57_1","unstructured":"Hospitalized adults: therapeutic management | COVID\u201019 Treatment Guidelines [Internet]. 2021.https:\/\/www.covid19treatmentguidelines.nih.gov\/management\/clinical-management\/hospitalized-adults--therapeutic-management\/"},{"key":"e_1_2_10_58_1","unstructured":"Therapeutics and COVID\u201019: living guideline [Internet]. 2021.\u00a0https:\/\/app.magicapp.org\/#\/guideline\/5666"},{"key":"e_1_2_10_59_1","unstructured":"COVID_Management_Algorithm_23092021.pdf [Internet]. 2021.https:\/\/www.icmr.gov.in\/pdf\/covid\/techdoc\/COVID_Management_Algorithm_23092021.pdf"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abe4724"}],"container-title":["Medicinal Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/med.21951","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/med.21951","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/med.21951","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T01:07:34Z","timestamp":1692234454000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/med.21951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1002\/med.21951"],"URL":"https:\/\/doi.org\/10.1002\/med.21951","archive":["Portico"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.26.21268434","asserted-by":"object"}]},"ISSN":["0198-6325","1098-1128"],"issn-type":[{"value":"0198-6325","type":"print"},{"value":"1098-1128","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]},"assertion":[{"value":"2022-01-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}